Medical Developments International (FRA:M5D) LT-Debt-to-Total-Asset: 0.02 (As of Dec. 2025)

What is Medical Developments International LT-Debt-to-Total-Asset?

Medical Developments International FRA:M5D +1.55% 32 LT-Debt-to-Total-Asset is 0.02 as of Dec. 2025. GuruFocus rates FRA:M5D with a GF Score™ of 32/100 and a GF Value™ of €0.35 (Significantly Undervalued). The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Medical Developments International's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.02.

Medical Developments International's long-term debt to total assets ratio declined from Dec. 2024 (0.03) to Dec. 2025 (0.02). It may suggest that Medical Developments International is progressively becoming less dependent on debt to grow their business.

Medical Developments International (FRA:M5D) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Medical Developments International LT-Debt-to-Total-Asset Related Terms

Medical Developments International LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Medical Developments International's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Developments International LT-Debt-to-Total-Asset Chart

Medical Developments International Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.02

0.03

Medical Developments International Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	0.03	0.03	0.03	0.02

32GF Score

Medical Developments International Ltd FRA:M5D

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Medical Developments International LT-Debt-to-Total-Asset Calculation

Medical Developments International's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )	/	Total Assets (A: Jun. 2025 )
	=	0.943	/	37.477
	=	0.03

Medical Developments International's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	0.853	/	36.071
	=	0.02

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.02 mean?

Medical Developments International (FRA:M5D) has a LT-Debt-to-Total-Asset of 0.02 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Medical Developments International and its competitors.

Is Medical Developments International's LT-Debt-to-Total-Asset too high?

Medical Developments International's current LT-Debt-to-Total-Asset is 0.02. Overall, Medical Developments International has a GF Score™ of 32/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Medical Developments International's LT-Debt-to-Total-Asset compare to ZTS?

Medical Developments International's LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Medical Developments International and its competitors. Medical Developments International's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Medical Developments International stock overvalued right now?

Based on GuruFocus' analysis, Medical Developments International (FRA:M5D) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.35, compared to a current price of €0.20 — trading 43.7% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.02. Medical Developments International's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Medical Developments International (FRA:M5D), the current LT-Debt-to-Total-Asset is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medical Developments International (FRA:M5D) Overvalued in 2026?

Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued. The current stock price of €0.20 is trading 43.7% below its estimated GF Value™ of €0.35. GuruFocus considers Medical Developments International to be Significantly Undervalued.

Key valuation signals for FRA:M5D:

LT-Debt-to-Total-Asset: 0.02
GF Value™: €0.35 vs. price of €0.20 (43.7% below fair value)
GF Score™: 32/100 with 2 warning signs

No single metric tells the full story. See the FRA:M5D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medical Developments International Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ASX:SNT ASX:LGP ASX:VIT ASX:PKP ASX:IDT ASX:EPN ASX:ECS ASX:PER ASX:CAN ASX:BP8 XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges MDDVF:USA MVP:Australia

Address 4 Caribbean Drive, Scoresby, VIC, AUS, 3179

Website https://www.medicaldev.com

Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.

32GF Score

Get the complete analysis for FRA:M5D

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20

Price

€0.35

GF Value

View FRA:M5D Analysis

See LT-Debt-to-Total-Asset data for all stocks →